Influence of radiotherapy on the immune function and prognosis of patients with esophageal cancer

doi:10.3760/cma.j.issn.1673422X.2016.12.002

Abstract

Abstract: ObjectiveTo observe the dynamic changes of the immune function in patients with esophageal cancer during the radiotherapy and also to explore its association with the clinical prognosis factors. MethodsTotally 90 cases with esophageal cancer received radiotherapy in Second Affiliated Hospital of Nantong University from January 2010 to December 2013 were collected. The proportions of Tlymphocyte subsets and natural killer (NK) cells in the peripheral blood were detected by the flow cytometry from start to finish and 3 months after radiotherapy. Meanwhile, 30 cases of healthy subjects were taken as control. The changes of the immune function in the patients during the radiotherapy and the correlation between the changes and clinicopathologic features were analyzed, as well as the clinical prognostic factors were further evaluated. ResultsThe difference of proportions of CD4+ T cells (28.23%±8.22%), CD8+ T cells (31.79%±7.61%), CD4+/CD8+ ratio (0.93±0.34) and NK cells (11.37%±4.57%) in preradiotherapy patients with esophageal cancer were statistically significant (t=4.292, P=0.000; t=2.811, P=0.006; t=5.894, P=0.000; t=3.965, P=0.000) compared with control group (36.03%±9.71%, 27.26%±7.70%, 1.34±0.27, 15.31%±5.13%); but the proportions of CD3+ T cells (58.13%±9.46%) had no obvious difference (t=0.988, P=0.325) compared with control group (60.06%±8.67%). The immune function of esophageal patients in 3 months after radiotherapy such as CD3+ (59.27%±9.92%), CD4+ (30.51%±9.04%), CD8+ (29.79%±6.98%) and NK cells (10.62%±4.43%) gradually returned to the preradiotherapy levels (t=0.789, P=0.431; t=1.769, P=0.079; t=1.837, P=0.068; t=1.113, P=0.267). The changes of immune function (CD4+, CD8+, CD4+/CD8+ ratio, NK cells) after radiotherapy were related to the bone marrow suppression (t=4.050, P=0.001; t=2.180, P=0.015; t=2.130, P=0.020; t=3.520, P=0.003) and irradiation volumes (t=5.170, P=0.000; t=3.350, P=0.026; t=8.750, P=0.000; t=2.490, P=0.043). Survival analysis showed that the patients whose immune function recovered better in 3 months after radiotherapy had a longer median survival time than those recovered bad (23 months vs. 17 months, χ2=6.820, P=0.009). ConclusionThe patients of esophageal cancer are immunosuppressive before radiotherapy and will further aggravated after radiotherapy. The degree of immunosuppression is associated with bone marrow suppression and irradiation volumes. The immune function of patients are recovered in 3 months after radiotherapy, and the patients whose immune function recovered better have good prognosis.

Key words: Esophageal neoplasms, Radiotherapy, Tlymphocyte subsets, Natural killer cells

WANG Xiao-Bo, WU Di-Jun, CHEN Wei-Ping, LIU Jian. Influence of radiotherapy on the immune function and prognosis of patients with esophageal cancer[J]. Journal of International Oncology, 2016, 43(12): 886-891.

References

1］ Liu JY, Li F, Wang LP, et al. CTLvs Treg lymphocyteattracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma［J］. Br J Cancer, 2015, 113(5): 747755. DOI: 10.1038/bjc.2015.290. ［2］ Wang G, Sun Y, Ji C, et al. Correlation between the CD4+CD25 high regulatory T cells and the outcome of chemotherapy in advanced esophageal carcinoma［J］. Hepatogastroenterology, 2013, 60(124): 704708. DOI: 10.5754/hge12953. ［3］王俞, 崔书中. 恶性肿瘤患者的免疫功能状态及免疫治疗研究进展［J］. 中国肿瘤临床, 2014, 41(13): 876879. DOI: 10.3969/j.issn.10008179.20131206. ［4］ Nabeki B, Ishigami S, Uchikado Y, et al. Interleukin32 expression and Treg infiltration in esophageal squamous cell carcinoma［J］. Anticancer Res, 2015, 35(5): 29412947. ［5］陈传生, 游涛, 林纲, 等. 同步放化疗对食管癌患者T淋巴细胞亚群及自然杀伤细胞的影响［J］. 海南医学院学报, 2014, 20(12): 17111713. DOI: 10.13210/j.cnki.jhmu.20141011.002. ［6］陈超, 李华峰. 放疗前后食管癌患者红细胞免疫功能和T淋巴细胞亚群的变化［J］. 浙江医学, 2015, 37(3): 229231. ［7］ Tsuchikawa T, Md MM, Yamamura Y, et al. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma［J］. Ann Surg Oncol, 2012, 19(5): 17131719. DOI: 10.1245/s104340111906x. ［8］ Reginato E, Lindenmann J, Langner C, et al. Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma［J］. Photochem Photobiol Sci, 2014, 13(9): 12811289. DOI: 10.1039/c4pp00186a. ［9］ Narita M, Kanda T, Abe T, et al. Immune responses in patients with esophageal cancer treated with SART1 peptidepulsed dendritic cell vaccine［J］. Int J Oncol, 2015, 46(4): 16991709. DOI: 10.3892/ijo.2015.2846. ［10］王胜根, 杨朝群. 放疗中不同等效方野对T淋巴细胞亚群和IL2的影响［J］. 农垦医学, 2007, 29(2): 105107. DOI: 10.3969/j.issn.10081127.2007.02.010. ［11］王忠明, 刘桂荣, 黄关宏, 等. 食管癌放疗患者T淋巴细胞和自然杀伤细胞水平的临床研究［J］. 肿瘤研究与临床, 2011, 23(10): 674677. DOI: 10.3760/cma.j.issn.10069801.2011.10.008.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[6]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[15]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.